AMENDMENT

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows:

IN THE CLAIMS:

Kindly amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows:

1. (Currently Amended) A vaccine ~~An immunogenic~~ composition to induce ~~an~~ a protective immune response against West Nile virus (WNV) in an animal susceptible to WNV comprising a vector comprising a recombinant virus or DNA plasmid that encodes and expresses *in vivo* in the animal WNV E; WNV prM and E; WNV M and E; WNV prM, WNV M and E, WNV polyprotein prM-E, WNV polyprotein M-E, or WNV polyprotein prM-M-E.

2. (Currently Amended) The vaccine ~~immunogenic~~ composition of claim 1 wherein the recombinant virus is a recombinant adenovirus, herpesvirus or poxvirus.

3. (Currently Amended) The vaccine ~~immunogenic~~ composition of claim 2 wherein the recombinant virus is a recombinant poxvirus.

4. (Currently Amended) The vaccine ~~immunogenic~~ composition of claim 3 wherein the recombinant poxvirus is a recombinant avipox virus.

5. (Currently Amended) The vaccine ~~immunogenic~~ composition of claim 4 wherein the recombinant avipox virus is a cannarypox or fowlpox virus.

6. (Currently Amended) The vaccine ~~immunogenic~~ composition of claim 5 wherein the canarypox virus is ALVAC and the fowlpox virus is TROVAC.

7. (Currently Amended) The vaccine ~~immunogenic~~ composition of claim 1 wherein the nucleic acid molecule is a coding frame encoding polyprotein prM-M-E.

8. (Currently Amended) The vaccine ~~immunogenic~~ composition of claim 5 wherein the nucleic acid molecule is a coding frame encoding polyprotein prM-M-E

9. (Currently Amended) The vaccine ~~immunogenic~~ composition of claim 6 wherein the nucleic acid molecule is a coding frame encoding polyprotein prM-M-E

10. (Currently Amended) The vaccine ~~immunogenic~~ composition of claim 1 wherein the nucleic acid molecule comprises nucleotides 466-741, 742-966 and 967-2469 of GenBank AF196835 encoding WNV prM, M and E, respectively.

11. (Currently Amended) The vaccine ~~immunogenic~~ composition of claim 1 wherein the nucleic acid molecule comprises nucleotides 466-2469 of GenBank AF196835 (SEQ ID NO: 66) encoding WN protein prM-M-E.

12. (Currently Amended) The vaccine ~~immunogenic~~ composition of claim 1 wherein the nucleic acid molecule comprises nucleotides 421-2469 of GenBank AF196835 (SEQ ID NO: 66) encoding WN protein prM-M-E and the signal peptide of prM.

13. (Currently Amended) The vaccine ~~immunogenic~~ composition of claim 1, further comprising an adjuvant.

14. (Currently Amended) The vaccine ~~immunogenic~~ composition according to claim 10, wherein the adjuvant is a carbomer.

15. (Currently Amended) The vaccine ~~immunogenic~~ composition of claim 1 further comprising an antigen or immunogen or epitope thereof of a pathogen other than WNV of the animal, or a vector that contains and expresses *in vivo* in the animal a nucleic acid molecule encoding the antigen, immunogen or epitope thereof, or an inactivated or attenuated pathogen other than WNV of the animal.

16. (Currently Amended) The vaccine ~~immunogenic~~ composition of claim 1, wherein the animal is a cat or a horse.

17. (Currently Amended) A method for inducing ~~an immunological or~~ a protective immune response against WNV in an animal comprising administering to the animal the ~~immunogenic or~~ vaccine composition according to claim 1.

18. (Currently Amended) A method for inducing ~~an immunological~~ a protective response against WNV in an animal comprising administering to the animal the immunogenic or vaccine composition according to claim 1~~7~~, wherein the composition additionally comprises an adjuvant.

19. (Currently Amended) The method according to claim 18 wherein the adjuvant comprises a carbomer adjuvant.

20. (Currently Amended) A method for inducing a protective immune ~~an immunological~~ response against WNV and a second pathogen in an animal ~~and against another~~

~~pathogen of the animal~~ comprising administering to the animal the immunogenic composition according to 1~~5~~9.

21. (Currently Amended) A method for inducing a protective immune ~~an immunological~~ response against WNV in an animal comprising administering to the animal (a) the vaccine ~~immunogenic~~ composition according to claim 1, and (b) a WNV isolated antigen, immunogen or epitope thereof, wherein (a) is administered prior to (b) in a prime-boost regimen, or (b) is administered prior to (a) in a prime-boost regimen, or (a) and (b) are administered together, either sequentially or in admixture.

22. (Original) The method of any of claims 17, 20 or 21, wherein the animal is a cat or a horse.

23-29. (Cancelled)